Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed
or refractory diffuse or mediastinal large B-cell lymphoma. Sunitinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the cancer.